Brain

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to KaziaSYDNEY, Sept. 22, 2026 /PRNewswire/ --...

UpRight Science Brings Together Expert Advisory Board to Advance Balance as an Essential Health Measure

Multidisciplinary group brings expertise across medicine, neuroscience, healthcare technology, business, and communications to support the company's mission to make balance...

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in 
DR Congo with 48% Crude Fatality Rate, Says NanoViricides

BRAINBox Solutions Announces Agreement with Prolight Diagnostics for Commercial Supply of Pyros® Devices for Delivery of BRAINBox Concussion Diagnostics/Prognostics at Point-of-Care

Company reports additional progress in expanding its patent portfolio for concussion and neurodegenerative disease testingRICHMOND, Va., Sept. 14, 2026 /PRNewswire/...

FINN Partners Named Global Agency of Record for AD/PD™ Conference, Advancing Breakthroughs in Neurodegenerative Disease

Partnership Leverages FINN's Specialized Experience in Brain Health Communications, Supporting a Shared Mission to Advance Translational Neuroscience WorldwideGENEVA, Sept. 14,...

Ahead of 9/11, U.S. Veterans’ Non-Profit Partners with World’s Only Medically Licensed Ayahuasca Facility to Combat PTSD and Suicide

This private, veteran-only retreat will offer medically supervised plant medicine treatment and long-term integration support for veterans living with treatment-resistant...

Brainomix and Endeavor BioMedicines Present Positive Results from Quantitative Image Analysis of Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Trial at ERS Congress

AI-powered quantitative CT analysis with Brainomix 360 e-Lung was used in Endeavor BioMedicines ENV-IPF-101 Phase 2a trial of taladegib. Results...

Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo

Rhelion Life Sciences’ Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurological Disorder

error: Content is protected !!